The document appears to be a calendar listing return dates and deadlines for various quality control and proficiency testing programmes offered by RIQAS. It includes the programme codes, sample numbers, and return dates for each month of 2017. It also provides brief descriptions of new programmes being offered, such as a liquid CSF control with a 30-day open vial stability, a CYFRA 21-1 programme for immunoassay quality control, and programmes for PTH, immunosuppressant drugs, and sweat testing.
There are different types of QC material and each format will have it's own advantages & disadvantages. Each format will also need to be handled differently and this guide aims to explain the different methods for preparing each type of control.
The laboratory shall determine measurement uncertainty for each measurement procedure,
in the examination phases used to report measured quantity values on patients’ samples. The
laboratory shall define the performance requirements for the measurement uncertainty of each
measurement procedure and regularly review estimates of measurement uncertainty.
Designing an appropriate QC procedure for your laboratoryRandox
Improving Laboratory Performance Through Quality Control - Five Simple Steps for QC Success.
It is easy to get caught up in an abundance of QC statistics and forget the fundamental reason why
QC exists in the first instance. QC is about detecting errors and ensuring that the results you
produce are accurate and reliable. All QC procedures should focus on reducing the risk of harm
to the patient. We are not examining statistics; we are examining real patients, real results and real
lives. Around 70% of all medical decisions are based on laboratory results, which is why it is of
utmost importance that each and every laboratory, has a well-designed QC procedure in place.
Troubleshooting Poor EQA/QC Performance in the Laboratory Randox
Step by step guide for clinical laboratories wishing to troubleshoot poor QC or EQA performance. Tips on how to distinguish between random error and systematic error. Suggested corrective actions are also provided.
Troubleshooting QC Problems: Your QC has failed, what do you do next?Randox
Randox Quality Control's next 'Improving Laboratory Performance Through Quality Control' educational guide has been published with helpful tips that your laboratory can use in order to ensure it has effective troubleshooting procedures in place.
So you ran QC this morning and realised that one of your analytes has been flagged as 'out-of-control', what do you do next? Do you ignore the warning and continue patient testing, repeat the control until it's within range or do you halt patient testing and investigate the source of the error?
When it comes to troubleshooting QC errors, unfortunately there is no easy path to take. However, it's important that you have standard operating procedures in place, outlining what to do in the event of an out-of control error. Errors occur in laboratories all over the world. A lab with effective troubleshooting procedures in place will still have errors but will be able to detect them, quickly reducing their impact and reducing the risk of wasting both time and money.
There are different types of QC material and each format will have it's own advantages & disadvantages. Each format will also need to be handled differently and this guide aims to explain the different methods for preparing each type of control.
The laboratory shall determine measurement uncertainty for each measurement procedure,
in the examination phases used to report measured quantity values on patients’ samples. The
laboratory shall define the performance requirements for the measurement uncertainty of each
measurement procedure and regularly review estimates of measurement uncertainty.
Designing an appropriate QC procedure for your laboratoryRandox
Improving Laboratory Performance Through Quality Control - Five Simple Steps for QC Success.
It is easy to get caught up in an abundance of QC statistics and forget the fundamental reason why
QC exists in the first instance. QC is about detecting errors and ensuring that the results you
produce are accurate and reliable. All QC procedures should focus on reducing the risk of harm
to the patient. We are not examining statistics; we are examining real patients, real results and real
lives. Around 70% of all medical decisions are based on laboratory results, which is why it is of
utmost importance that each and every laboratory, has a well-designed QC procedure in place.
Troubleshooting Poor EQA/QC Performance in the Laboratory Randox
Step by step guide for clinical laboratories wishing to troubleshoot poor QC or EQA performance. Tips on how to distinguish between random error and systematic error. Suggested corrective actions are also provided.
Troubleshooting QC Problems: Your QC has failed, what do you do next?Randox
Randox Quality Control's next 'Improving Laboratory Performance Through Quality Control' educational guide has been published with helpful tips that your laboratory can use in order to ensure it has effective troubleshooting procedures in place.
So you ran QC this morning and realised that one of your analytes has been flagged as 'out-of-control', what do you do next? Do you ignore the warning and continue patient testing, repeat the control until it's within range or do you halt patient testing and investigate the source of the error?
When it comes to troubleshooting QC errors, unfortunately there is no easy path to take. However, it's important that you have standard operating procedures in place, outlining what to do in the event of an out-of control error. Errors occur in laboratories all over the world. A lab with effective troubleshooting procedures in place will still have errors but will be able to detect them, quickly reducing their impact and reducing the risk of wasting both time and money.
QC Multi-rules are designed and used to minimise false rejections and maintain a high rate of error detection. There are six main rules used to determine if results from a run of patient samples should be accepted or rejected, based on the performance of control materials against the rule criteria. Different combinations can be applied depending on the number of controls in use, total allowable error and the instrument in use. The flow chart below is often used to determine if a run should be accepted or rejected.
Basic QC Statistics - Improving Laboratory Performance Through Quality Contro...Randox
Randox Quality Control's latest educational guide examines Internal Quality Control, External Quality Assessment, Why laboratories should run QC, How often laboratories should run QC, Basic QC statistics and the quality control process.
Monitoring External Quality Assessment / Proficiency Testing Performance - Investigating the source of the problem.
In order to identify the source of the problem it is useful to be aware of the most common causes of poor EQA performance. Errors can occur at any
stage of the testing process however EQA is most concerned with detecting analytical errors i.e. errors that occur during the analysis of the sample.
Most analytical errors can be easily divided into three main areas; clerical errors, systematic errors and random errors. Systematic errors result in
inaccurate results that consistently show a positive or negative bias. Random errors on the other hand affect precision and result in fluctuations in
either direction.
Multi-reglas de control de calidad (CC) son diseñadas y utilizadas para minimizar falsos rechazos y mantener una alta tasa de detección de errores. Hay seis reglas principales que son utilizadas para determinar si los resultados de una serie de muestras de pacientes deben ser aceptadas o rechazadas, basadas en el rendimiento de los materiales de control contra los criterios de las reglas. Diferentes combinaciones pueden ser aplicadas en función del número de controles, al error total permisible y al instrumento en uso. El siguiente diagrama de flujo se usa a menudo para determinar si una corrida debe ser aceptada o rechazada.
Acusera 24.7 Interlaboratory Data Management Randox
Acusera 24•7 Live Online is an interlaboratory data management package designed to complement the Acusera range of Internal Quality Controls. Created to help laboratories effectively manage and interpret their QC results, the analytical capabilities of Acusera 24•7 Live Online, coupled with the superior quality and flexibility of our Acusera control range, will revolutionise your laboratory's workflow enabling early identification of any trends or system errors.
Acusera 24.7 Live Online will automatically calculate internal QC statistics including mean, standard deviation and CV. The ability to apply user defined QC multi-rules will help to reduce false rejections and maintain a high level of error detection.
Online access anytime, anywhere
Peer group data from over 20,000 participants
Peer group statistics updated daily
Unique dashboard highlights poor performance
Interactive charts combining multiple analytes, lots and instruments
Comprehensive reports including audit trail reports to aid accreditation
Automated QC result entry via Acusera 24•7 Connect
How often is Right for Laboratory Quality Control?Randox
Improving Laboratory Performance Through QC - How often is right for QC? Ask the Right Questions to get the Right Answers.
It is widely accepted that laboratories should perform QC at least every day of patient testing. However, is this adequate for every assay and for every laboratory? Is running QC once per day really sufficient? what is the "right" frequency for running QC samples in your laboratory?
Acusera Third Party Quality Controls for Medical Laboratories Randox
With over 350 parameters available in our Acusera range, choice and flexibility is guaranteed. Moreover the availability of truly independent third party controls coupled with the added advantages of highly accurate target values, increased stability and unparalleled quality will optimise performance, save valuable time and minimise waste in any laboratory.
Our comprehensive range of multi-analyte controls have been uniquely developed with ease of use in mind, combining up to 100 parameters in one convenient control laboratories can significantly reduce the need for multiple, costly single analyte controls.
Consolidation
100% human controls for immunoassay purposes
Most accurate target values
Unrivalled stability
Most consistent controls
True third party controls
Learning Objectives:
Describe the consequences of hyper- and hypovolemia for surgical and critically ill patients.
Develop a fluid management strategy for individual patients
QC Multi-rules are designed and used to minimise false rejections and maintain a high rate of error detection. There are six main rules used to determine if results from a run of patient samples should be accepted or rejected, based on the performance of control materials against the rule criteria. Different combinations can be applied depending on the number of controls in use, total allowable error and the instrument in use. The flow chart below is often used to determine if a run should be accepted or rejected.
Basic QC Statistics - Improving Laboratory Performance Through Quality Contro...Randox
Randox Quality Control's latest educational guide examines Internal Quality Control, External Quality Assessment, Why laboratories should run QC, How often laboratories should run QC, Basic QC statistics and the quality control process.
Monitoring External Quality Assessment / Proficiency Testing Performance - Investigating the source of the problem.
In order to identify the source of the problem it is useful to be aware of the most common causes of poor EQA performance. Errors can occur at any
stage of the testing process however EQA is most concerned with detecting analytical errors i.e. errors that occur during the analysis of the sample.
Most analytical errors can be easily divided into three main areas; clerical errors, systematic errors and random errors. Systematic errors result in
inaccurate results that consistently show a positive or negative bias. Random errors on the other hand affect precision and result in fluctuations in
either direction.
Multi-reglas de control de calidad (CC) son diseñadas y utilizadas para minimizar falsos rechazos y mantener una alta tasa de detección de errores. Hay seis reglas principales que son utilizadas para determinar si los resultados de una serie de muestras de pacientes deben ser aceptadas o rechazadas, basadas en el rendimiento de los materiales de control contra los criterios de las reglas. Diferentes combinaciones pueden ser aplicadas en función del número de controles, al error total permisible y al instrumento en uso. El siguiente diagrama de flujo se usa a menudo para determinar si una corrida debe ser aceptada o rechazada.
Acusera 24.7 Interlaboratory Data Management Randox
Acusera 24•7 Live Online is an interlaboratory data management package designed to complement the Acusera range of Internal Quality Controls. Created to help laboratories effectively manage and interpret their QC results, the analytical capabilities of Acusera 24•7 Live Online, coupled with the superior quality and flexibility of our Acusera control range, will revolutionise your laboratory's workflow enabling early identification of any trends or system errors.
Acusera 24.7 Live Online will automatically calculate internal QC statistics including mean, standard deviation and CV. The ability to apply user defined QC multi-rules will help to reduce false rejections and maintain a high level of error detection.
Online access anytime, anywhere
Peer group data from over 20,000 participants
Peer group statistics updated daily
Unique dashboard highlights poor performance
Interactive charts combining multiple analytes, lots and instruments
Comprehensive reports including audit trail reports to aid accreditation
Automated QC result entry via Acusera 24•7 Connect
How often is Right for Laboratory Quality Control?Randox
Improving Laboratory Performance Through QC - How often is right for QC? Ask the Right Questions to get the Right Answers.
It is widely accepted that laboratories should perform QC at least every day of patient testing. However, is this adequate for every assay and for every laboratory? Is running QC once per day really sufficient? what is the "right" frequency for running QC samples in your laboratory?
Acusera Third Party Quality Controls for Medical Laboratories Randox
With over 350 parameters available in our Acusera range, choice and flexibility is guaranteed. Moreover the availability of truly independent third party controls coupled with the added advantages of highly accurate target values, increased stability and unparalleled quality will optimise performance, save valuable time and minimise waste in any laboratory.
Our comprehensive range of multi-analyte controls have been uniquely developed with ease of use in mind, combining up to 100 parameters in one convenient control laboratories can significantly reduce the need for multiple, costly single analyte controls.
Consolidation
100% human controls for immunoassay purposes
Most accurate target values
Unrivalled stability
Most consistent controls
True third party controls
Learning Objectives:
Describe the consequences of hyper- and hypovolemia for surgical and critically ill patients.
Develop a fluid management strategy for individual patients
dr Franciscus Ginting - Sepsis PIN PAPDI Surabaya WS-051019.pdfcorinafiqliyin
Penegakan diagnosis sepsis sangat diperlukan dalam kasus sepsis itu sendiri. Sepsis dapat disebabkan oleh beberapa hal. Salah satu komplikasi yang dapat timbul adalah syok sepis
The study to measure the level of serum annexin V in patients with renal hype...inventionjournals
ABSTRACT : Renovascular hypertension reflects the causal relation between anatomically evident arterial occlusive disease and elevated blood pressure. The coexistence of renal arterial vascular disease and hypertension roughly defines this type of nonessential hypertension. The aim of this study was to measure the level of serum Anti-Annexin V antibodies in patients with renal hypertension. Methods. This study was conducted on 115 patients, diagnosed with renal hypertension and hypertension. Informed consents were obtained from the patients and the study was approved by the Kharkiv National Medical University ethics committee. Ten healthy age and sex matched volunteers were included as a control group. All patients and controls were subjected to the following full history taking and thorough clinical examination. Routine laboratory testing included a complete blood count, and erythrocyte sedimentation rate (ESR) and kidney function tests (blood urea nitrogen and serum creatinine). Immunological tests for antinuclear antibody (ANA) and anticentromere antibodies (ACA) was performed by the indirect immunofluorescence technique. AntiScl-70 (anti-topoisomerase antibodies) and anticardiolipin antibodies (ACA: IgG and IgM) were tested using the ELISA technique. The anti-annexin V antibodies titre used the ZYMUTEST anti-Annexin IgG ELISA kit. [Hyphen-BioMed, France.]: to measure the IgG isotype of auto-antibodies to annexin V in human serum. Results. Anti-annexin V antibodies were present in 75% of patients (mean 83.46 ± 22.44 AU/mL) vs. 0% in the controls (mean 3.94 ± 4.5 AU/mL). Comparison between patients and controls as regards levels of anti-annexin V showed a highly significant difference (P < 0.001). Furthermore, correlation of anti-annexin V titres with the disease activity score in the patient group showed a statistically significant positive correlation (r = 0.51, P < 0.05).In addition, the anti-annexin V antibody titres in this study showed a highly significant positive correlation with ACL antibodies (r = 0.74, P < 0.001). Patients with antiphospholipid syndrome (APS) have been known to have a higher frequency of anti-annexin V antibodies, and thrombotic events have been reported more frequently in patients with positive anti-annexin V antibodies. Furthermore, inhibition of annexin V binding to negatively charged phospholipids may be an additional pathogenic mechanism of APS.
This talk begins by showing how accurately 4000 different diagnoses can be predicted in advance for any patient, from one month to twenty years before first occurrence in the patient, using high-throughput machine learning. Shortcomings of this approach motivate ways to turn prediction methods into algorithms for finding causal associations; the resulting algorithms attain high accuracy in tasks of drug repurposing and discovery of adverse drug events, but they do not come with provable guarantees of making correct causal inferences. We then introduce variants of probably-approximately correct (PAC) learning for finding causal associations, that can provide weaker but useful guarantees for such algorithms as these motivated by our experiences with EHR data.
Keynote presentation for Network Biology SIG 2013 by Esti Yeger-Lotem, Senior Lecturer in Clinical Biochemistry at The National Institute for Biotechnology in the Negev, Israel
Survival of Esophageal Cancer Patients was Significantly Superior in Comparison with Cardioesophageal Cancer Patients after Surgery
Kshivets Oleg Surgery Department, Roshal Hospital, Moscow, Russia
OBJECTIVE: This study aimed to determine localization influence of tumor for 5-year survival (5YS) of esophageal (EC) or cardioesophageal (CC) cancer patients (ECP, CEP) after complete en block (R0) esophagogastrectomies (EG) through left/right thoracoabdominal incision.
METHODS: We analyzed data of 543 consecutive patients (age=56.4±8.8 years; tumor size=6±3.5 cm) radically operated (R0) and monitored in 1975-2019 (m=405, f=138; ECP=259, CEP=284; esophagogastrectomies (EG) Garlock=280, EG Lewis=263, combined EG with resection of pancreas, liver, diaphragm, aorta, VCS, colon transversum, lung, trachea, pericardium, splenectomy=151; adenocarcinoma=308, squamous=225, mix=10; T1=126, T2=114, T3=178, T4=125; N0=275, N1=69, N2=199; G1=157, G2=139, G3=247; early EC=107, invasive=436; only surgery=420, adjuvant chemoimmunoradiotherapy-AT=123: 5-FU+thymalin/taktivin+radiotherapy 45-50Gy). Multivariate Cox modeling, clustering, SEPATH, Monte Carlo, bootstrap and neural networks computing were used to determine any significant dependence.
RESULTS: Overall life span (LS) was 1892.4±2241 days and cumulative 5-year survival (5YS) reached 51.9%, 10 years – 45.7%, 20 years – 33.5%. 183 ECP lived more than 5 years (LS=4311±2419.7 days), 98 ECP – more than 10 years (LS=5903.4±2299.4 days). 224 died because of EC/CC (LS=629.2±320.1 days). 5YS of ECP (67.3%, LS=2605±2628.9 days) was significantly superior in comparison with CEP (36.4%, LS=1242.6±1558.5 days) (P=0.00000 by log-rank test). AT significantly improved 5YS (68.2% vs. 48.5%) (P=0.00033 by log-rank test). Cox modeling displayed that 5YS of ECP/CEP significantly depended on: phase transition (PT) N0—N12 in terms of synergetics, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), T, G, histology, age, AT, localization, blood cells, prothrombin index, coagulation time, residual nitrogen, blood group, Rh, glucose, protein (P=0.000-0.008). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and healthy cells/CC (rank=1), PT early-invasive EC (rank=2), PT N0—N12 (rank=3), erythrocytes/CC (4), thrombocytes/CC (5), stick neutrophils/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), eosinophils/CC (9), leucocytes/CC (10), monocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
2017 11-28 European Alliance for Personalised Medicine Congressm 2017, Belfas...Alain van Gool
Lecture to outline the added value of intergrating genomics with proteomics, glycomics and metabolomics to create novel personalized diagnostics and drive personalised healthcare.
How to establish QC reference ranges - Randox QC Educational GuideRandox
Establishing QC reference ranges is an important aspect of laboratory quality. Find out how to effectively set reference ranges with our educational guide.
Randox QC offer an extensive range of third party quality controls. Manufactured independently, the Acusera range delivers unbiased performance assessment with any instrument or method, helping to meet ISO 15189:2012 requirements whilst simultaneously eliminating the need for multiple instrument dedicated controls.
Acusera 24.7 is an interboratory data management software capable of automatically calculating measurement of uncertainty and six-sigma. With real time peer group updates and user friendly comprehensive charts and reports including Levey Jennings and histograms, our Acusera 24.7 software is now smarter, faster and more efficient than ever before!
Acusera 24.7 Interlaboratory Data Management - June 17 LT244Randox
Acusera 24.7 Live Online version 2.0 is here! Faster, smarter and more efficient than ever before, this interlaboratory data management program will be sure to help streamline internal QC in all laboratories regardless of size.
Acusera Verify Linearity Verification - June 17 LT674Randox
Our Acusera Linearity Sets are perfect for laboratories wishing to challenge the full reportable range of their instruments. With sets available for Roche & Beckman analysers, our sets are sure to meet all your laboratory and regulatory requirements.
RIQAS is the largest international External Quality Assessment (EQA)/ Proficiency Testing (PT) scheme, there are currently more than 45,000 participants in 133 countries.
White Paper Quality Control for Point of Care TestingRandox
Point of care testing (POCT) refers to testing that is performed near or at the site of a patient with the result leading to a possible change in the care of the patient.
QC Multi rules - Improving Laboratory Performance Through Quality ControlRandox
Randox Quality Control's latest educational guide examines and explains what QC Multi-Rules are, How to identify an out of control event with QC rules, How to use QC Multi-Rules, The different types of analytical errors, The tools to assist labs and how a lab can troubleshoot QC errors.
Improving Laboratory Performance Through Quality Control - The role of EQA in...Randox
Randox Quality Control's five simple steps to QC success. The second education guide from Randox QC for clinical laboratory staff. The guide will examine how EQA works, benefits of EQA and what a laboratory should look for when choosing an EQA scheme.
Chandrima Spa Ajman is one of the leading Massage Center in Ajman, which is open 24 hours exclusively for men. Being one of the most affordable Spa in Ajman, we offer Body to Body massage, Kerala Massage, Malayali Massage, Indian Massage, Pakistani Massage Russian massage, Thai massage, Swedish massage, Hot Stone Massage, Deep Tissue Massage, and many more. Indulge in the ultimate massage experience and book your appointment today. We are confident that you will leave our Massage spa feeling refreshed, rejuvenated, and ready to take on the world.
Visit : https://massagespaajman.com/
Call : 052 987 1315
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Dr. David Greene R3 stem cell Breakthroughs: Stem Cell Therapy in CardiologyR3 Stem Cell
Dr. David Greene, founder and CEO of R3 Stem Cell, is at the forefront of groundbreaking research in the field of cardiology, focusing on the transformative potential of stem cell therapy. His latest work emphasizes innovative approaches to treating heart disease, aiming to repair damaged heart tissue and improve heart function through the use of advanced stem cell techniques. This research promises not only to enhance the quality of life for patients with chronic heart conditions but also to pave the way for new, more effective treatments. Dr. Greene's work is notable for its focus on safety, efficacy, and the potential to significantly reduce the need for invasive surgeries and long-term medication, positioning stem cell therapy as a key player in the future of cardiac care.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Trauma Outpatient Center is a comprehensive facility dedicated to addressing mental health challenges and providing medication-assisted treatment. We offer a diverse range of services aimed at assisting individuals in overcoming addiction, mental health disorders, and related obstacles. Our team consists of seasoned professionals who are both experienced and compassionate, committed to delivering the highest standard of care to our clients. By utilizing evidence-based treatment methods, we strive to help our clients achieve their goals and lead healthier, more fulfilling lives.
Our mission is to provide a safe and supportive environment where our clients can receive the highest quality of care. We are dedicated to assisting our clients in reaching their objectives and improving their overall well-being. We prioritize our clients' needs and individualize treatment plans to ensure they receive tailored care. Our approach is rooted in evidence-based practices proven effective in treating addiction and mental health disorders.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Rate Controlled Drug Delivery Systems, Activation Modulated Drug Delivery Systems, Mechanically activated, pH activated, Enzyme activated, Osmotic activated Drug Delivery Systems, Feedback regulated Drug Delivery Systems systems are discussed here.
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDr Rachana Gujar
Introduction: Substance use education is crucial due to its prevalence and societal impact.
Alcohol Use: Immediate and long-term risks include impaired judgment, health issues, and social consequences.
Tobacco Use: Immediate effects include increased heart rate, while long-term risks encompass cancer and heart disease.
Drug Use: Risks vary depending on the drug type, including health and psychological implications.
Prevention Strategies: Education, healthy coping mechanisms, community support, and policies are vital in preventing substance use.
Harm Reduction Strategies: Safe use practices, medication-assisted treatment, and naloxone availability aim to reduce harm.
Seeking Help for Addiction: Recognizing signs, available treatments, support systems, and resources are essential for recovery.
Personal Stories: Real stories of recovery emphasize hope and resilience.
Interactive Q&A: Engage the audience and encourage discussion.
Conclusion: Recap key points and emphasize the importance of awareness, prevention, and seeking help.
Resources: Provide contact information and links for further support.
Under Pressure : Kenneth Kruk's StrategyKenneth Kruk
Kenneth Kruk's story of transforming challenges into opportunities by leading successful medical record transitions and bridging scientific knowledge gaps during COVID-19.
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac CareDr. David Greene Arizona
Explore the groundbreaking work of Dr. David Greene, a pioneer in regenerative medicine, who is revolutionizing the field of cardiology through stem cell therapy in Arizona. This ppt delves into how Dr. Greene's innovative approach is providing non-surgical, effective treatments for heart disease, using the body's own cells to repair heart damage and improve patient outcomes. Learn about the science behind stem cell therapy, its benefits over traditional cardiac surgeries, and the promising future it holds for modern medicine. Join us as we uncover how Dr. Greene's commitment to stem cell research and therapy is setting new standards in healthcare and offering new hope to cardiac patients.
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareVITASAuthor
This webinar helps clinicians understand the unique healthcare needs of the LGBTQ+ community, primarily in relation to end-of-life care. Topics include social and cultural background and challenges, healthcare disparities, advanced care planning, and strategies for reaching the community and improving quality of care.
Feeding plate for a newborn with Cleft Palate.pptxSatvikaPrasad
A feeding plate is a prosthetic device used for newborns with a cleft palate to assist in feeding and improve nutrition intake. From a prosthodontic perspective, this plate acts as a barrier between the oral and nasal cavities, facilitating effective sucking and swallowing by providing a more normal anatomical structure. It helps to prevent milk from entering the nasal passage, thereby reducing the risk of aspiration and enhancing the infant's ability to feed efficiently. The feeding plate also aids in the development of the oral muscles and can contribute to better growth and weight gain. Its custom fabrication and proper fitting by a prosthodontist are crucial for ensuring comfort and functionality, as well as for minimizing potential complications. Early intervention with a feeding plate can significantly improve the quality of life for both the infant and the parents.
2. CY
MI
LC
HI
BG
I
P
H
D
U
CR
L
CC Clinical Chemistry
Cardiac
Therapeutic Drugs
Haematology
Specific Proteins
Immunoassay
Lipids
Human Urine
Blood Gas
Coagulation
HbA1c
Liquid Cardiac
BNP
Monthly Immunoassay
TI
RI
MS
UR
EB
BN
TX
AE
HB
Maternal Screening
Immunoassay Speciality 2
Immunoassay Speciality 1
UrineToxicology
Urinalysis
Ammonia/Ethanol
Serology - EBV
Serology - HIV/Hepatitis
Serology -ToRCH
Serology - Syphilis
ESR
Anti-TSH Receptor
CYFRA 21-1
CSF
CO SY
TO
ES
CF
CS
AT
TU
TS
TB
TP
SweatTesting
Immunosuppressant
Trace Elements in Blood
Trace Elements in Serum
Trace Elements in Urine
Programme Code
Dates shown indicate the 17.00 hrs GMT FINAL DATE DEADLINE for arrival of results at RIQAS HQ.Cycle No
Sample NoCC
55 9 +44 (0) 28 9442 2413 | mail@riqas.com | riqas.com
January 2017 Return Dates
Monday
2nd
9th
16th
23rd
30th
TX
9 1
RI
7 1
BN
4 1
UR
9 1
LC
9 1
H
44 9
CO
9 1
H
44 10
I
46 1
CC
55 9
I
46 2
10CC
55
TI
7 1P
55 9
HB
12 1
P
55 10
L
36 1
CR
31 9
L
36 2
10CR
31
BG
9 1
MS
9 1
MI
15 1
U
50 1
D
55 9
U
50 2
D
55 10 AE
3 5
I
46 3 L
36 3 U
50 3 TP
1 11CY
1 11AT
1 11 CS
1 11 CF
1 11 TS
1 11TB
1 11 TU
1 11
3. New Acusera Liquid CSF Control
With an extended open vial stability of 30
days, our CSF control will reduce waste,
whilst remaining easy and convenient to use.
Monday Tuesday Wednesday Thursday Friday Saturday Sunday
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31
January 2017
4. CY
MI
LC
HI
BG
I
P
H
D
U
CR
L
CC Clinical Chemistry
Cardiac
Therapeutic Drugs
Haematology
Specific Proteins
Immunoassay
Lipids
Human Urine
Blood Gas
Coagulation
HbA1c
Liquid Cardiac
BNP
Monthly Immunoassay
TI
RI
MS
UR
EB
BN
TX
AE
HB
Maternal Screening
Immunoassay Speciality 2
Immunoassay Speciality 1
UrineToxicology
Urinalysis
Ammonia/Ethanol
Serology - EBV
Serology - HIV/Hepatitis
Serology -ToRCH
Serology - Syphilis
ESR
Anti-TSH Receptor
CYFRA 21-1
CSF
CO SY
TO
ES
CF
CS
AT
TU
TS
TB
TP
SweatTesting
Immunosuppressant
Trace Elements in Blood
Trace Elements in Serum
Trace Elements in Urine
Programme Code
Dates shown indicate the 17.00 hrs GMT FINAL DATE DEADLINE for arrival of results at RIQAS HQ.Cycle No
Sample NoCC
55 9 +44 (0) 28 9442 2413 | mail@riqas.com | riqas.com
February 2017 Return Dates
Monday
6th
13th
20th
27th
RI
7 2
H
44 11
H
44 12 CO
9 2
CC
55 11
12CC
55
I
46 4 TI
7 2
P
55 11
P
55 12 HB
12 2
CR
31 11
12CR
31
L
36 4 BG
9 2
MS
9 2
D
55 11
D
55 12
U
50 4
AE
3 6
TX
9 2BN
4 2LC
9 2
MI
15 2
I
46 5 L
36 5 U
50 5 TP
1 12CY
1 12AT
1 11 CS
1 12 CF
1 12 TS
1 12TB
1 12 TU
1 12
5. Monday Tuesday Wednesday Thursday Friday Saturday Sunday
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28
February 2017
New RIQAS CYFRA 21-1 Programme
Designed to complement our range of
Immunoassay andTumour Marker Quality
Control solutions, the new RIQAS CYFRA
21-1 programme offers monthly analysis
and online result submission.
6. CY
MI
LC
HI
BG
I
P
H
D
U
CR
L
CC Clinical Chemistry
Cardiac
Therapeutic Drugs
Haematology
Specific Proteins
Immunoassay
Lipids
Human Urine
Blood Gas
Coagulation
HbA1c
Liquid Cardiac
BNP
Monthly Immunoassay
TI
RI
MS
UR
EB
BN
TX
AE
HB
Maternal Screening
Immunoassay Speciality 2
Immunoassay Speciality 1
UrineToxicology
Urinalysis
Ammonia/Ethanol
Serology - EBV
Serology - HIV/Hepatitis
Serology -ToRCH
Serology - Syphilis
ESR
Anti-TSH Receptor
CYFRA 21-1
CSF
CO SY
TO
ES
CF
CS
AT
TU
TS
TB
TP
SweatTesting
Immunosuppressant
Trace Elements in Blood
Trace Elements in Serum
Trace Elements in Urine
Programme Code
Dates shown indicate the 17.00 hrs GMT FINAL DATE DEADLINE for arrival of results at RIQAS HQ.Cycle No
Sample NoCC
55 9 +44 (0) 28 9442 2413 | mail@riqas.com | riqas.com
March 2017 Return Dates
Monday
6th
13th
20th
27th
RI
7 3
H
45 1 CO
9 3
CC
55 13
1CC
56
I
46 6 TI
7 3
P
56 1 HB
12 31CR
32
L
36 6 BG
9 3
MS
9 3D
56 1
U
50 6
AE
3 7
TX
9 3BN
4 3LC
9 3
MI
15 3
I
46 7 L
36 7 U
50 7
CS
2 1 CF
2 1
TS
2 1TB
2 1 TU
2 1
AT
2 1UR
9 2 TO
5 D SY
5 DEB
5 D HI
5 D ES
3 A
TP
2 1
CY
2 1
7. Monday Tuesday Wednesday Thursday Friday Saturday Sunday
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31
March 2017
New Acusera PTH Control
Providing a true third party solution for
the measurement of Intact PTH, the new
Acusera PTH Control is available now
with a 30 day open vial stability, reducing
waste and costs.
8. CY
MI
LC
HI
BG
I
P
H
D
U
CR
L
CC Clinical Chemistry
Cardiac
Therapeutic Drugs
Haematology
Specific Proteins
Immunoassay
Lipids
Human Urine
Blood Gas
Coagulation
HbA1c
Liquid Cardiac
BNP
Monthly Immunoassay
TI
RI
MS
UR
EB
BN
TX
AE
HB
Maternal Screening
Immunoassay Speciality 2
Immunoassay Speciality 1
UrineToxicology
Urinalysis
Ammonia/Ethanol
Serology - EBV
Serology - HIV/Hepatitis
Serology -ToRCH
Serology - Syphilis
ESR
Anti-TSH Receptor
CYFRA 21-1
CSF
CO SY
TO
ES
CF
CS
AT
TU
TS
TB
TP
SweatTesting
Immunosuppressant
Trace Elements in Blood
Trace Elements in Serum
Trace Elements in Urine
Programme Code
Dates shown indicate the 17.00 hrs GMT FINAL DATE DEADLINE for arrival of results at RIQAS HQ.Cycle No
Sample NoCC
55 9 +44 (0) 28 9442 2413 | mail@riqas.com | riqas.com
April 2017 Return Dates
Monday
3rd
10th
17th
24th
RI
7 4
H
45 2
CO
9 4
2CC
56
I
46 8 TI
7 4
P
56 2
HB
12 4
2CR
32
L
36 8 BG
9 4
MS
9 4
D
56 2
U
50 8
AE
3 8
TX
9 4BN
4 4LC
9 4
MI
15 4I
46 9 L
36 9 U
50 9
CS
2 2 CF
2 2
TS
2 2TB
2 2 TU
2 2AT
2 2
TP
2 2
CY
2 2
H
45 33CC
56
P
56 33CR
32
D
56 3
9. Monday Tuesday Wednesday Thursday Friday Saturday Sunday
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
April 2017
New RIQAS Immunosuppressant
Programme
The recently launched RIQAS
Immunosuppressant programme combines
four commonly tested immunosuppressant
drugs in a single sample, helping to ensure
high quality patient testing.
10. CY
MI
LC
HI
BG
I
P
H
D
U
CR
L
CC Clinical Chemistry
Cardiac
Therapeutic Drugs
Haematology
Specific Proteins
Immunoassay
Lipids
Human Urine
Blood Gas
Coagulation
HbA1c
Liquid Cardiac
BNP
Monthly Immunoassay
TI
RI
MS
UR
EB
BN
TX
AE
HB
Maternal Screening
Immunoassay Speciality 2
Immunoassay Speciality 1
UrineToxicology
Urinalysis
Ammonia/Ethanol
Serology - EBV
Serology - HIV/Hepatitis
Serology -ToRCH
Serology - Syphilis
ESR
Anti-TSH Receptor
CYFRA 21-1
CSF
CO SY
TO
ES
CF
CS
AT
TU
TS
TB
TP
SweatTesting
Immunosuppressant
Trace Elements in Blood
Trace Elements in Serum
Trace Elements in Urine
Programme Code
Dates shown indicate the 17.00 hrs GMT FINAL DATE DEADLINE for arrival of results at RIQAS HQ.Cycle No
Sample NoCC
55 9 +44 (0) 28 9442 2413 | mail@riqas.com | riqas.com
May 2017 Return Dates
Monday
1st
8th
15th
22nd
29th
RI
7 5
H
45 4
CO
9 5
4CC
56
I
46 10 TI
7 5
P
56 4
HB
12 5
4CR
32
L
36 10 BG
9 5
MS
9 5
D
56 4
U
50 10
AE
3 9
TX
9 5BN
4 5LC
9 5
MI
15 5I
46 11 L
36 11 U
50 11
CS
2 3 CF
2 3
TS
2 3TB
2 3 TU
2 3AT
2 3
TP
2 3
CY
2 3
H
45 55CC
56
P
56 55CR
32
D
56 5
UR
9 3
H
45 66CC
56
P
56 66CR
32
D
56 6
11. Monday Tuesday Wednesday Thursday Friday Saturday Sunday
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31
May 2017
New RIQAS Sweat Testing Programme
Combining Sodium, Chloride and
Conductivity in a convenient liquid
ready-to-use format, the RIQAS Sweat
Testing programme is designed to reduce
preparation time whilst helping to ensure
accurate diagnosis of Cystic Fibrosis.
12. CY
MI
LC
HI
BG
I
P
H
D
U
CR
L
CC Clinical Chemistry
Cardiac
Therapeutic Drugs
Haematology
Specific Proteins
Immunoassay
Lipids
Human Urine
Blood Gas
Coagulation
HbA1c
Liquid Cardiac
BNP
Monthly Immunoassay
TI
RI
MS
UR
EB
BN
TX
AE
HB
Maternal Screening
Immunoassay Speciality 2
Immunoassay Speciality 1
UrineToxicology
Urinalysis
Ammonia/Ethanol
Serology - EBV
Serology - HIV/Hepatitis
Serology -ToRCH
Serology - Syphilis
ESR
Anti-TSH Receptor
CYFRA 21-1
CSF
CO SY
TO
ES
CF
CS
AT
TU
TS
TB
TP
SweatTesting
Immunosuppressant
Trace Elements in Blood
Trace Elements in Serum
Trace Elements in Urine
Programme Code
Dates shown indicate the 17.00 hrs GMT FINAL DATE DEADLINE for arrival of results at RIQAS HQ.Cycle No
Sample NoCC
55 9 +44 (0) 28 9442 2413 | mail@riqas.com | riqas.com
June 2017 Return Dates
Monday
5th
12th
19th
26th
RI
7 6
CO
9 6
I
46 12
TI
7 6
HB
12 6
L
36 12
BG
9 6
MS
9 6
U
50 12
AE
3 10
TX
9 6BN
4 6LC
9 6
MI
15 6
CS
2 4 CF
2 4
TS
2 4
TO
6 A SY
6 AEB
6 A HI
6 A ES
3 B
TB
2 4 TU
2 4AT
2 4
TP
2 4
CY
2 4
H
45 77CC
56
P
56 77CR
32
D
56 7
H
45 88CC
56
P
56 88CR
32
D
56 8
13. Monday Tuesday Wednesday Thursday Friday Saturday Sunday
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30
June 2017
New RIQAS Anti-TSH Receptor
Programme
Perfectly complementing our existing
Immunoassay and Immunoassay Speciality I
programmes, the new Anti-TSH Receptor
programme helps to deliver a total
EQA solution for thyroid hormones and
antibodies.
14. CY
MI
LC
HI
BG
I
P
H
D
U
CR
L
CC Clinical Chemistry
Cardiac
Therapeutic Drugs
Haematology
Specific Proteins
Immunoassay
Lipids
Human Urine
Blood Gas
Coagulation
HbA1c
Liquid Cardiac
BNP
Monthly Immunoassay
TI
RI
MS
UR
EB
BN
TX
AE
HB
Maternal Screening
Immunoassay Speciality 2
Immunoassay Speciality 1
UrineToxicology
Urinalysis
Ammonia/Ethanol
Serology - EBV
Serology - HIV/Hepatitis
Serology -ToRCH
Serology - Syphilis
ESR
Anti-TSH Receptor
CYFRA 21-1
CSF
CO SY
TO
ES
CF
CS
AT
TU
TS
TB
TP
SweatTesting
Immunosuppressant
Trace Elements in Blood
Trace Elements in Serum
Trace Elements in Urine
Programme Code
Dates shown indicate the 17.00 hrs GMT FINAL DATE DEADLINE for arrival of results at RIQAS HQ.Cycle No
Sample NoCC
55 9 +44 (0) 28 9442 2413 | mail@riqas.com | riqas.com
July 2017 Return Dates
Monday
3rd
10th
17th
24th
31st
RI
7 7
CO
9 7
I
47 1
TI
7 7
HB
12 7
L
37 1
BG
9 7
MS
9 7
U
51 1
AE
3 11
TX
9 7BN
4 7LC
9 7
CS
2 5 CF
2 5
TS
2 5TB
2 5 TU
2 5AT
2 5
H
45 99CC
56
P
56 99CR
32
D
56 9
H
45 1010CC
56
P
56 1010CR
32
D
56 10
I
47 2 L
37 2 U
51 2
UR
9 4
MI
15 7I
47 3 L
37 3 U
51 3
TP
2 5
CY
2 5
15. Monday Tuesday Wednesday Thursday Friday Saturday Sunday
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31
July 2017
New Acusera Verify Linearity Sets
Covering a wide range of Cardiac Markers,
Therapeutic Drugs and Specific Proteins,
the new AcuseraVerify range of linearity
materials will help to ensure accurate
performance across the complete
reportable range.
16. CY
MI
LC
HI
BG
I
P
H
D
U
CR
L
CC Clinical Chemistry
Cardiac
Therapeutic Drugs
Haematology
Specific Proteins
Immunoassay
Lipids
Human Urine
Blood Gas
Coagulation
HbA1c
Liquid Cardiac
BNP
Monthly Immunoassay
TI
RI
MS
UR
EB
BN
TX
AE
HB
Maternal Screening
Immunoassay Speciality 2
Immunoassay Speciality 1
UrineToxicology
Urinalysis
Ammonia/Ethanol
Serology - EBV
Serology - HIV/Hepatitis
Serology -ToRCH
Serology - Syphilis
ESR
Anti-TSH Receptor
CYFRA 21-1
CSF
CO SY
TO
ES
CF
CS
AT
TU
TS
TB
TP
SweatTesting
Immunosuppressant
Trace Elements in Blood
Trace Elements in Serum
Trace Elements in Urine
Programme Code
Dates shown indicate the 17.00 hrs GMT FINAL DATE DEADLINE for arrival of results at RIQAS HQ.Cycle No
Sample NoCC
55 9 +44 (0) 28 9442 2413 | mail@riqas.com | riqas.com
August 2017 Return Dates
Monday
7th
14th
21st
28th
RI
7 8
CO
9 8
TI
7 8
HB
12 8
BG
9 8
MS
9 8
AE
3 12
TX
9 8BN
4 8LC
9 8
CS
2 6 CF
2 6
TS
2 6TB
2 6 TU
2 6AT
2 6
H
45 1111CC
56
P
56 1111CR
32
D
56 11
I
47 4 L
37 4 U
51 4
H
45 1212CC
56
P
56 1212CR
32
D
56 12
MI
15 8I
47 5 L
37 5 U
51 5
TP
2 6
CY
2 6
17. Monday Tuesday Wednesday Thursday Friday Saturday Sunday
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31
August 2017
Acusera 24•7 Live Online now
automatically calculating Sigma Metrics
& Measurement Uncertainty
Managing lab performance and assessing
the quality of the results you produce is
now even easier & more effective with
Acusera 24•7 Live Online’ s latest features.
18. CY
MI
LC
HI
BG
I
P
H
D
U
CR
L
CC Clinical Chemistry
Cardiac
Therapeutic Drugs
Haematology
Specific Proteins
Immunoassay
Lipids
Human Urine
Blood Gas
Coagulation
HbA1c
Liquid Cardiac
BNP
Monthly Immunoassay
TI
RI
MS
UR
EB
BN
TX
AE
HB
Maternal Screening
Immunoassay Speciality 2
Immunoassay Speciality 1
UrineToxicology
Urinalysis
Ammonia/Ethanol
Serology - EBV
Serology - HIV/Hepatitis
Serology -ToRCH
Serology - Syphilis
ESR
Anti-TSH Receptor
CYFRA 21-1
CSF
CO SY
TO
ES
CF
CS
AT
TU
TS
TB
TP
SweatTesting
Immunosuppressant
Trace Elements in Blood
Trace Elements in Serum
Trace Elements in Urine
Programme Code
Dates shown indicate the 17.00 hrs GMT FINAL DATE DEADLINE for arrival of results at RIQAS HQ.Cycle No
Sample NoCC
55 9 +44 (0) 28 9442 2413 | mail@riqas.com | riqas.com
September 2017 Return Dates
Monday
4th
11th
18th
25th
RI
7 9
TO
6 B SY
6 BEB
6 B HI
6 B ES
3 C
CO
9 9
TI
7 9
HB
12 9
BG
9 9
MS
9 9
AE
4 1
TX
9 9BN
4 9LC
9 9
CS
2 7 CF
2 7
TS
2 7TB
2 7 TU
2 7
AT
2 7
13CC
56
I
47 6 L
37 6 U
51 6
H
46 11CC
57
P
57 11CR
33
D
57 1
MI
15 9
I
47 7 L
37 7 U
51 7
TP
2 7
CY
2 7UR
9 5
20. CY
MI
LC
HI
BG
I
P
H
D
U
CR
L
CC Clinical Chemistry
Cardiac
Therapeutic Drugs
Haematology
Specific Proteins
Immunoassay
Lipids
Human Urine
Blood Gas
Coagulation
HbA1c
Liquid Cardiac
BNP
Monthly Immunoassay
TI
RI
MS
UR
EB
BN
TX
AE
HB
Maternal Screening
Immunoassay Speciality 2
Immunoassay Speciality 1
UrineToxicology
Urinalysis
Ammonia/Ethanol
Serology - EBV
Serology - HIV/Hepatitis
Serology -ToRCH
Serology - Syphilis
ESR
Anti-TSH Receptor
CYFRA 21-1
CSF
CO SY
TO
ES
CF
CS
AT
TU
TS
TB
TP
SweatTesting
Immunosuppressant
Trace Elements in Blood
Trace Elements in Serum
Trace Elements in Urine
Programme Code
Dates shown indicate the 17.00 hrs GMT FINAL DATE DEADLINE for arrival of results at RIQAS HQ.Cycle No
Sample NoCC
55 9 +44 (0) 28 9442 2413 | mail@riqas.com | riqas.com
October 2017 Return Dates
Monday
2nd
9th
16th
23th
30th
RI
7 10
CO
9 10
TI
7 10
HB
12 10
BG
9 10
MS
9 10
AE
4 2
TX
9 10BN
4 10LC
9 10
CS
2 8 CF
2 8
TS
2 8TB
2 8 TU
2 8AT
2 8
I
47 8 L
37 8 U
51 8
H
46 33CC
57
P
57 33CR
33
D
57 3
MI
15 10I
47 9 L
37 9 U
51 9
TP
2 8
CY
2 8
H
46 22CC
57
P
57 22CR
33
D
57 2
H
46 44CC
57
P
57 44CR
33
D
57 4
21. Monday Tuesday Wednesday Thursday Friday Saturday Sunday
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31
October 2017
New RIQAS Trace Elements
Programmes
With the recent expansion of RIQAS,
three new trace element programmes
covering whole blood, serum and urine are
now available with monthly analysis.
25 54.938
Mn
Manganese
81 204.38
Tl
Thallium
42 95.94
Mo
Molybdenum
12 24.305
Mg
Magnesium
34 78.96
Se
Selenium
53 126.90
I
Iodine
24 51.996
Cr
Chromium
27 58.933
Co
Cobalt
48 112.41
Cd
Cadmium
28 58.693
Ni
Nickel
82 207.2
Pb
Lead
22. CY
MI
LC
HI
BG
I
P
H
D
U
CR
L
CC Clinical Chemistry
Cardiac
Therapeutic Drugs
Haematology
Specific Proteins
Immunoassay
Lipids
Human Urine
Blood Gas
Coagulation
HbA1c
Liquid Cardiac
BNP
Monthly Immunoassay
TI
RI
MS
UR
EB
BN
TX
AE
HB
Maternal Screening
Immunoassay Speciality 2
Immunoassay Speciality 1
UrineToxicology
Urinalysis
Ammonia/Ethanol
Serology - EBV
Serology - HIV/Hepatitis
Serology -ToRCH
Serology - Syphilis
ESR
Anti-TSH Receptor
CYFRA 21-1
CSF
CO SY
TO
ES
CF
CS
AT
TU
TS
TB
TP
SweatTesting
Immunosuppressant
Trace Elements in Blood
Trace Elements in Serum
Trace Elements in Urine
Programme Code
Dates shown indicate the 17.00 hrs GMT FINAL DATE DEADLINE for arrival of results at RIQAS HQ.Cycle No
Sample NoCC
55 9 +44 (0) 28 9442 2413 | mail@riqas.com | riqas.com
November 2017 Return Dates
Monday
6th
13th
20th
27th
RI
7 11
CO
9 11
TI
7 11
HB
12 11
BG
9 11
MS
9 11
AE
4 3
TX
9 11BN
4 11LC
9 11
CS
2 9 CF
2 9
TS
2 9TB
2 9 TU
2 9AT
2 9
I
47 10 L
37 10 U
51 10
MI
15 11
TP
2 9
CY
2 9
H
46 55CC
57
P
57 55CR
33
D
57 5
I
47 11 L
37 11 U
51 11
H
46 66CC
57
P
57 66CR
33
D
57 6 UR
9 6
24. CY
MI
LC
HI
BG
I
P
H
D
U
CR
L
CC Clinical Chemistry
Cardiac
Therapeutic Drugs
Haematology
Specific Proteins
Immunoassay
Lipids
Human Urine
Blood Gas
Coagulation
HbA1c
Liquid Cardiac
BNP
Monthly Immunoassay
TI
RI
MS
UR
EB
BN
TX
AE
HB
Maternal Screening
Immunoassay Speciality 2
Immunoassay Speciality 1
UrineToxicology
Urinalysis
Ammonia/Ethanol
Serology - EBV
Serology - HIV/Hepatitis
Serology -ToRCH
Serology - Syphilis
ESR
Anti-TSH Receptor
CYFRA 21-1
CSF
CO SY
TO
ES
CF
CS
AT
TU
TS
TB
TP
SweatTesting
Immunosuppressant
Trace Elements in Blood
Trace Elements in Serum
Trace Elements in Urine
Programme Code
Dates shown indicate the 17.00 hrs GMT FINAL DATE DEADLINE for arrival of results at RIQAS HQ.Cycle No
Sample NoCC
55 9 +44 (0) 28 9442 2413 | mail@riqas.com | riqas.com
December 2017 Return Dates
Monday /Wednesday
4th
11th
18th
27th
RI
7 12
CO
9 12
TI
7 12
HB
12 12
BG
9 12
MS
9 12
TX
9 12BN
4 12LC
9 12
CS
2 10 CF
2 10
TS
2 10TB
2 10 TU
2 10
AT
2 10
I
47 12 L
37 12 U
51 12
MI
15 12TP
2 10
CY
2 10
H
46 77CC
57
P
57 77CR
33
D
57 7
H
46 88CC
57
P
57 88CR
33
D
57 8 TO
6 C SY
6 CEB
6 C HI
6 C ES
3 DAE
4 4
25. Monday Tuesday Wednesday Thursday Friday Saturday Sunday
1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31
December 2017
Acusera True Third Party Controls
Designed to help today’s busy laboratories
reduce the number of individual controls
required to cover their test menu, the
Acusera range will dramatically reduce
costs and preparation time without
sacrificing on quality.